{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:09:48Z","timestamp":1768640988427,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,7,10]],"date-time":"2011-07-10T00:00:00Z","timestamp":1310256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11255-011-0028-5","type":"journal-article","created":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T06:12:13Z","timestamp":1310191933000},"page":"499-507","source":"Crossref","is-referenced-by-count":33,"title":["Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD"],"prefix":"10.1007","volume":"44","author":[{"given":"Peter","family":"Van Buren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben L.","family":"Velez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nosratola D.","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,10]]},"reference":[{"key":"28_CR1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ncpneph0847","volume":"8","author":"N Vaziri","year":"2008","unstructured":"Vaziri N (2008) Anemia and anemia correction: surrogate markers or causes of mortality in chronic kidney disease. Nat Clin Pract Nephrol 8:436\u2013445","journal-title":"Nat Clin Pract Nephrol"},{"key":"28_CR2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","volume":"24","author":"N Vaziri","year":"2009","unstructured":"Vaziri N, Zhou X (2009) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24:1082\u20131088","journal-title":"Nephrol Dial Transplant"},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","volume":"10","author":"J Ma","year":"1999","unstructured":"Ma J, Ebben J, Xia H, Collins A (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610\u2013619","journal-title":"J Am Soc Nephrol"},{"key":"28_CR4","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1681\/ASN.V12112465","volume":"12","author":"A Collins","year":"2001","unstructured":"Collins A, Li S, Peter W et al (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36\u201339%. J Am Soc Nephrol 12:2465\u20132473","journal-title":"J Am Soc Nephrol"},{"key":"28_CR5","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1523-1755.2005.00693.x","volume":"68","author":"B Robinson","year":"2005","unstructured":"Robinson B, Joffe M, Berns J, Pisoni R, Port F, Feldman H (2005) Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68:2323\u20132330","journal-title":"Kidney Int"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Pisoni R, Combe C et al (2004) Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 19:121\u2013132","journal-title":"Nephrol Dial Transplant"},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.V1061309","volume":"10","author":"H Xia","year":"1999","unstructured":"Xia H, Ebben J, Ma J, Collins A (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309\u20131316","journal-title":"J Am Soc Nephrol"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1523-1755.2004.00425.x","volume":"65","author":"S Li","year":"2004","unstructured":"Li S, Collins A (2004) Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65:626\u2013633","journal-title":"Kidney Int"},{"key":"28_CR9","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1046\/j.1523-1755.2003.00937.x","volume":"63","author":"N Ofsthun","year":"2003","unstructured":"Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus J (2003) The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908\u20131914","journal-title":"Kidney Int"},{"key":"28_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2004.09.023","volume":"45","author":"R Wolfe","year":"2002","unstructured":"Wolfe R, Hulbert-Shearon T, Ashby V, Mahadevan S, Port F (2002) Improvements in dialysis patient mortality are associated with improvements in urea reduction ration and hematocrit, 1999\u20132002. Am J Kidney Dis 45:127\u2013135","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 4","key":"28_CR11","first-page":"S1","volume":"47","author":"NKF-K\/DOQI","year":"2006","unstructured":"NKF-K\/DOQI (2006) Clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 47(Suppl 4):S1","journal-title":"Am J Kidney Dis"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton W, Browne J et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339:584\u2013590","journal-title":"New Engl J Med"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"T Drueke","year":"2006","unstructured":"Drueke T, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 355:2071\u20132084","journal-title":"New Engl J Med"},{"key":"28_CR14","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"A Singh","year":"2006","unstructured":"Singh A, Szczech L, Tang K et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 355:2085\u20132098","journal-title":"New Engl J Med"},{"key":"28_CR15","first-page":"474","volume":"50","author":"NKF-K\/DOQI","year":"2007","unstructured":"NKF-K\/DOQI (2007) Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:474","journal-title":"Am J Kidney Dis"},{"key":"28_CR16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1053\/ajkd.2001.29280","volume":"38","author":"M Spittle","year":"2001","unstructured":"Spittle M, Hoenich N, Handelman G, Adhikarla R, Homel P, Levin N (2001) Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408\u20131413","journal-title":"Am J Kidney Dis"},{"key":"28_CR17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813\u2013820","journal-title":"Nature"},{"key":"28_CR18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/hr.2011.39","volume":"34","author":"E Schulz","year":"2011","unstructured":"Schulz E, Gori T, Munzel T (2011) Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 34:665\u2013673","journal-title":"Hypertens Res"},{"key":"28_CR19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"L Szczech","year":"2008","unstructured":"Szczech L, Barnhart H, Inrig J et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791\u2013798","journal-title":"Kidney Int"},{"key":"28_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5414\/CNP63092","volume":"63","author":"C Kuo","year":"2005","unstructured":"Kuo C, Lee C, Chuang C, Su Y, Chen J (2005) Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis. Clin Nephrol 63:92\u201397","journal-title":"Clin Nephrol"},{"key":"28_CR21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1681\/ASN.2010020173","volume":"22","author":"DF Goodkin","year":"2011","unstructured":"Goodkin DF, Fuller DS, Robinson B et al (2011) Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358\u2013365","journal-title":"J Am Soc Nephrol"},{"key":"28_CR22","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2004121039","volume":"16","author":"P Parfrey","year":"2005","unstructured":"Parfrey P, Foley R, Wittreich B et al (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180\u20132189","journal-title":"J Am Soc Nephrol"},{"key":"28_CR23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1525-139X.2009.00620.x","volume":"22","author":"D Goodkin","year":"2009","unstructured":"Goodkin D (2009) The normal hematocrit cardiac trial revisited. Semin Dial 22:495\u2013502","journal-title":"Semin Dial"},{"key":"28_CR24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V50.3.433.433","volume":"50","author":"A Jacobs","year":"1977","unstructured":"Jacobs A (1977) Low molecular weight intracellular iron transport compounds. Blood 50:433\u2013439","journal-title":"Blood"},{"key":"28_CR25","doi-asserted-by":"crossref","first-page":"8440","DOI":"10.1073\/pnas.88.19.8440","volume":"88","author":"M Burkitt","year":"1991","unstructured":"Burkitt M, Mason R (1991) Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: An ESR spin-trapping investigation. Proc Natl Acad Sci USA 88:8440\u20138444","journal-title":"Proc Natl Acad Sci USA"},{"key":"28_CR26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.freeradbiomed.2009.08.004","volume":"47","author":"K Broedbaek","year":"2009","unstructured":"Broedbaek K, Poulsen H, Weimann A et al (2009) Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 47:1230\u20131233","journal-title":"Free Radic Biol Med"},{"key":"28_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-8794-2-2","volume":"2","author":"D Kell","year":"2009","unstructured":"Kell D (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2:2","journal-title":"BMC Med Genomics"},{"key":"28_CR28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.1999.01170.x","volume":"104","author":"S Beshara","year":"1999","unstructured":"Beshara S, Lundquist H, Sundin J et al (1999) Kinetic analysis of 52 Fe-labelled iron (III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br J Hematol 104:288\u2013295","journal-title":"Br J Hematol"},{"key":"28_CR29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/oxfordjournals.ndt.a027405","volume":"11","author":"A Zanen","year":"1996","unstructured":"Zanen A, Adriaansen H, van Bommel E, Posthuma R, de Jong G (1996) Oversaturation of transferrin after intravenous ferric gluconate (ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11:820\u2013824","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"28_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2362.2002.0320s1036.x","volume":"32","author":"M Kooistra","year":"2002","unstructured":"Kooistra M, Kersting S, Lu G et al (2002) Nontransferrin-bound iron in the plasma of the haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Investig 32(Suppl 1):36\u201341","journal-title":"Eur J Clin Investig"},{"key":"28_CR31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.V34.3.357.357","volume":"34","author":"P Henderson","year":"1969","unstructured":"Henderson P, Hillman R (1969) Characteristics of iron dextran utilization in man. Blood 34:357\u2013375","journal-title":"Blood"},{"key":"28_CR32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ndt\/gfg579","volume":"19","author":"D Wyck Van","year":"2004","unstructured":"Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19:561\u2013565","journal-title":"Nephrol Dial Transplant"},{"key":"28_CR33","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0006-2952(03)00181-3","volume":"65","author":"B Scheiber-Mojdehkar","year":"2003","unstructured":"Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H (2003) Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65:1973\u20131978","journal-title":"Biochem Pharmacol"},{"key":"28_CR34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.02840608","volume":"4","author":"R Provenzano","year":"2009","unstructured":"Provenzano R, Schiller B, Rao M et al (2009) Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4:386\u2013393","journal-title":"Clin J Am Soc Nephrol"},{"key":"28_CR35","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","volume":"19","author":"B Spinowitz","year":"2008","unstructured":"Spinowitz B, Kausz A, Baptista J et al (2008) Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19:1599\u20131605","journal-title":"J Am Soc Nephrol"},{"key":"28_CR36","doi-asserted-by":"crossref","first-page":"F426","DOI":"10.1152\/ajprenal.00248.2010","volume":"299","author":"A Johnson","year":"2010","unstructured":"Johnson A, Becker K, Zager R (2010) Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Renal Phys 299:F426\u2013F435","journal-title":"Am J Renal Phys"},{"key":"28_CR37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu M, Suh K, Lee H, Cohen M, Rieves D, Pazdur R (2010) FDA review of ferumoxytol (feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease. Am J Hematol 85:315\u2013319","journal-title":"Am J Hematol"},{"key":"28_CR38","volume-title":"USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States","author":"US Renal Data System","year":"2010","unstructured":"US Renal Data System (2010) USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, Bethesda"},{"key":"28_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/ajkd.2002.33917","volume":"40","author":"R Zager","year":"2002","unstructured":"Zager R, Johnson C, Hanson S, Wasse H (2002) Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90\u2013103","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"28_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2362.2002.0320s1009.x","volume":"32","author":"T Rooyakers","year":"2002","unstructured":"Rooyakers T, Stroes E, Kooistra M et al (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Investig 32(Suppl 1):9\u201316","journal-title":"Eur J Clin Investig"},{"key":"28_CR41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1681\/ASN.V113539","volume":"11","author":"J Roob","year":"2000","unstructured":"Roob J, Khoschsorur G, Tiran A et al (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539\u2013549","journal-title":"J Am Soc Nephrol"},{"key":"28_CR42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1440-1797.2009.01174.x","volume":"15","author":"N Garcia-Fernandez","year":"2010","unstructured":"Garcia-Fernandez N, Echevarria A, Sanchez-Ibarrola A, Paramo J, Coma-Cannela I (2010) Randomized clinical trial on acute effects of i.v. iron sucrose during hemodialysis. Nephrology 15:178\u2013183","journal-title":"Nephrology"},{"key":"28_CR43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1046\/j.1523-1755.2001.00976.x","volume":"60","author":"A Salahudeen","year":"2001","unstructured":"Salahudeen A, Oliver B, Bower J, Roberts L (2001) Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525\u20131531","journal-title":"Kidney Int"},{"key":"28_CR44","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1681\/ASN.2007101084","volume":"19","author":"K Kuo","year":"2008","unstructured":"Kuo K, Hung S, Wei Y, Tarng D (2008) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 19:1817\u20131826","journal-title":"J Am Soc Nephrol"},{"key":"28_CR45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/ajkd.2002.36334","volume":"40","author":"D Tovbin","year":"2002","unstructured":"Tovbin D, Mazour D, Voroblov M, Chalmovitz C, Meyerstein N (2002) Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005\u20131012","journal-title":"Am J Kidney Dis"},{"key":"28_CR46","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1523-1755.2004.00648.x","volume":"65","author":"R Agarwal","year":"2004","unstructured":"Agarwal R, Vasavada N, Sachs N, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279\u20132289","journal-title":"Kidney Int"},{"key":"28_CR47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.V103594","volume":"10","author":"J Kielstein","year":"1999","unstructured":"Kielstein J, Boger R, Bode-Boger S (1999) Asymmetric dimethyl arginine concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594\u2013600","journal-title":"J Am Soc Nephrol"},{"key":"28_CR48","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","volume":"358","author":"C Zoccali","year":"2001","unstructured":"Zoccali C, Bode-Boger S, Mallamaci F et al (2001) Plasma concentrations of asymmetrical dimethyl arginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113\u20132117","journal-title":"Lancet"},{"key":"28_CR49","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1681\/ASN.2005121379","volume":"17","author":"K Matsuguma","year":"2006","unstructured":"Matsuguma K, Ueda S, Yamagishi S et al (2006) Molecular mechanisms for elevation of asymmetric dimethyl arginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17:2176\u20132183","journal-title":"J Am Soc Nephrol"},{"key":"28_CR50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1096\/fj.05-4700fje","volume":"20","author":"A Kartikasari","year":"2006","unstructured":"Kartikasari A, Georgiou N, Visseren F, van Kats-Renaud H, van Sweder A, Marx J (2006) Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J 20:353\u2013355","journal-title":"FASEB J"},{"key":"28_CR51","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/j.1523-1755.2005.00754.x","volume":"68","author":"G Schaller","year":"2005","unstructured":"Schaller G, Scheibert-Mohdehkar B, Wolzt M et al (2005) Intravenous iron increases labile serum iron but does not impair blood flow reactivity in dialysis patients. Kidney Int 68:2814\u20132822","journal-title":"Kidney Int"},{"key":"28_CR52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1536\/ihj.46.255","volume":"46","author":"K Reis","year":"2005","unstructured":"Reis K, Guz G, Ozdemir H et al (2005) Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease. Int Heart J 46:255\u2013264","journal-title":"Int Heart J"},{"key":"28_CR53","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/01.CIR.103.23.2799","volume":"103","author":"S Duffy","year":"2001","unstructured":"Duffy S, Biegelsen E, Holbrook M et al (2001) Iron chelation improves endothelial cell function in patients with coronary artery disease. Circulation 103:2799\u20132804","journal-title":"Circulation"},{"key":"28_CR54","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/j.1523-1755.2005.00565.x","volume":"68","author":"R Zager","year":"2005","unstructured":"Zager R (2005) Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68:1533\u20131542","journal-title":"Kidney Int"},{"key":"28_CR55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.ki.5000164","volume":"69","author":"R Agarwal","year":"2006","unstructured":"Agarwal R (2006) Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69:1259\u20131263","journal-title":"Kidney Int"},{"key":"28_CR56","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1523-1755.2003.00099.x","volume":"64","author":"G Weiss","year":"2003","unstructured":"Weiss G, Meusberger E, Radacher G, Garimorth K, Neyer U, Myaer G (2003) Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64:572\u2013578","journal-title":"Kidney Int"},{"key":"28_CR57","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1523-1755.2000.00337.x","volume":"58","author":"M Sarnak","year":"2000","unstructured":"Sarnak M, Jaber B (2000) Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58:1758\u20131764","journal-title":"Kidney Int"},{"key":"28_CR58","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato S, Chmielewski M, Honda H et al (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3:1526\u20131533","journal-title":"Clin J Am Soc Nephrol"},{"key":"28_CR59","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0167-4889(92)90062-G","volume":"1133","author":"A Djeha","year":"1992","unstructured":"Djeha A, Brock J (1992) Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biopys Acta 1133:147\u2013152","journal-title":"Biochem Biopys Acta"},{"key":"28_CR60","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1755.2003.00125.x","volume":"64","author":"R Deicher","year":"2003","unstructured":"Deicher R, Ziai F, Cohen G, Mullner M, Horl W (2003) High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64:728\u2013736","journal-title":"Kidney Int"},{"key":"28_CR61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5414\/CNP58134","volume":"58","author":"D Guo","year":"2002","unstructured":"Guo D, Jaber B, Lee S et al (2002) Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 58:134\u2013142","journal-title":"Clin Nephrol"},{"key":"28_CR62","first-page":"11","volume":"17","author":"A Gupta","year":"2010","unstructured":"Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A (2010) Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 17:11\u201316","journal-title":"BMC Nephrol"},{"key":"28_CR63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1042\/BJ20041650","volume":"387","author":"M Tenopoulou","year":"2005","unstructured":"Tenopoulou M, Doulias P, Barbouti A, Brunk U, Galaris D (2005) Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem J 387:703\u2013710","journal-title":"Biochem J"},{"key":"28_CR64","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1523-1755.2004.00716.x","volume":"66","author":"R Zager","year":"2004","unstructured":"Zager R, Johnson A, Hanson S (2004) Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 66:144\u2013156","journal-title":"Kidney Int"},{"key":"28_CR65","doi-asserted-by":"crossref","first-page":"F265","DOI":"10.1152\/ajprenal.00318.2004","volume":"288","author":"R Agarwal","year":"2005","unstructured":"Agarwal R (2005) On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol 288:F265\u2013F271","journal-title":"Am J Physiol Renal Physiol"},{"key":"28_CR66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/sj.ki.5002422","volume":"72","author":"R Agarwal","year":"2007","unstructured":"Agarwal R, Rizkala A, Kaskas M, Minasian R, Trout J (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72:638\u2013642","journal-title":"Kidney Int"},{"key":"28_CR67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ndt\/gfh565","volume":"20","author":"D Leehey","year":"2005","unstructured":"Leehey D, Palubiak D, Chebrolu S, Agarwal R (2005) Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 20:135\u2013140","journal-title":"Nephrol Dial Transplant"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-0028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-011-0028-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-0028-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T15:52:15Z","timestamp":1712591535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-011-0028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,10]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s11255-011-0028-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,10]]}}}